Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon

Samaha et al., Viruses, doi:10.3390/v13060989 (results 1/16)
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
This study was retracted.
Samaha et al., 16 Jan 2021, peer-reviewed, 16 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Ali A Samaha, Hussein Mouawia, Mirna Fawaz, Hamad Hassan, Ali Salami, Ali Al Bazzal, Hamid Bou Saab, Mohamed Al-Wakeel, Ahmad Alsaabi, Mohamad Chouman, Mahmoud Al Moussawi, Hassan Ayoub, Ali Raad, Ola Hajjeh, Ali H Eid, Houssam Raad
Viruses, doi:10.3390/v13060989
Objective: This study was designed to determine the efficacy of ivermectin, an FDAapproved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference (p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. In the ivermectin group, Ct increased from 15.13 ± 2.07 (day zero) to 30.14 ± 6.22 (day three; mean ± SD), compared to the control group, where the Ct values increased only from 14.20 ± 2.48 (day zero) to 18.96 ± 3.26 (day three; mean ± SD). Moreover, more subjects in the control group developed clinical symptoms. Three individuals (6%) required hospitalization, compared to the ivermectin group (0%). Conclusion: Ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2-positive subjects, effectively resulting in fewer symptoms, lower viral load and reduced hospital admissions. However, larger-scale trials are warranted for this conclusion to be further cemented.
Conflicts of Interest: The authors declare no conflict of interest.
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.191
Alexander, Tinkov, Strand, Alehagen, Skalny et al., Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19, Nutrients, doi:10.3390/nu12082358
Arévalo, Pagotto, Pórfido, Daghero, Segovia et al., Ivermectin reduces coronavirus infection in vivo: A mouse experimental model, bioRxiv, doi:10.1101/2020.11.02.363242
Booz, Altara, Eid, Wehbe, Fares et al., Macrophage responses associated with COVID-19: A pharmacological perspective, Eur. J. Pharmacol, doi:10.1016/j.ejphar.2020.173547
Buonfrate, Salas-Coronas, Munoz, Maruri, Rodari et al., Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial, Lancet Infect. Dis, doi:10.1016/S1473-3099(19)30289-0
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res, doi:10.1016/j.antiviral.2020.104787
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
Dingens, Crawford, Adler, Steele, Lacombe et al., Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak, Nat. Commun, doi:10.1038/s41467-020-18178-1
Dinicolantonio, Barroso, Mccarty, Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart, doi:10.1136/openhrt-2020-001350
Finzi, Harrington, Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients, J. Med. Virol, doi:10.1002/jmv.26812
Giordo, Zinellu, Eid, Pintus, Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders, Molecules, doi:10.3390/molecules26040856
Gotz, Magar, Dornfeld, Giese, Pohlmann et al., Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci. Rep, doi:10.1038/srep23138
Hall, Jr, Ji, A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease, Travel. Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101646
Hammoud, Wehbe, Abdelhady, Kobeissy, Eid et al., Dysregulation of Angiotensin Converting Enzyme 2 Expression and Function in Comorbid Disease Conditions Possibly Contributes to Coronavirus Infectious Disease 2019 Complication Severity, Mol. Pharmacol, doi:10.1124/molpharm.120.000119
Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq, doi:10.1101/2020.10.26.20219345
Hu, Guo, Zhou, Shi, Characteristics of SARS-CoV-2 and COVID-19, Nat. Rev. Microbiol
Hussein, Elkhair, Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19, J. Mol. Struct, doi:10.1016/j.molstruc.2021.129979
Jans, Martin, Wagstaff, Inhibitors of nuclear transport, Curr. Opin. Cell Biol, doi:10.1016/
Joob, Wiwanitkit, COVID-19 can present with a rash and be mistaken for dengue, J. Am. Acad. Dermatol, doi:10.1016/j.jaad.2020.03.036
Kaddoura, Alibrahim, Hijazi, Soudani, Audi et al., COVID-19 Therapeutic Options Under Investigation, Front. Pharmacol, doi:10.3389/fphar.2020.01196
Kampf, Lemmen, Suchomel, Ct values and infectivity of SARS-CoV-2 on surfaces, Lancet Infect. Dis, doi:10.1016/S1473-3099(20)30883-5
Kaur, Shekhar, Sharma, Sarma, Prakash et al., Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes, Pharmacol. Rep, doi:10.1007/s43440-020-00195-y
Kinobe, Owens, A systematic review of experimental evidence for antiviral effects of ivermectin and an in-silico analysis of ivermectin's possible mode of action against SARS-CoV-2, Fundam Clin. Pharmacol, doi:10.1111/fcp.12644
Lorenz, Dias Bocewicz, Correa De Azevedo Marques, Reis Santana, Chiaravalloti-Neto et al., Have measures against COVID-19 helped to reduce dengue cases in Brazil? Travel, Med. Infect. Dis
Martin, Jans, Antivirals that target the host IMPalpha/beta1-virus interface, Biochem. Soc. Trans, doi:10.1042/BST20200568
Navarro, Camprubi, Requena-Mendez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: A systematic review and meta-analysis, J. Antimicrob. Chemother, doi:10.1093/jac/dkz524
Noreen, Maqbool, Madni, Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic, Eur. J. Pharmacol, doi:10.1016/j.ejphar.2021.173854
Pujadas, Chaudhry, Mcbride, Richter, Zhao et al., SARS-CoV-2 viral load predicts COVID-19 mortality, Lancet Respir. Med, doi:10.1016/S2213-2600(20)30354-4
Rabi, Al Zoubi, Kasasbeh, Salameh, Al-Nasser, SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far, Pathogens, doi:10.3390/pathogens9030231
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study, Chest
Shakkour, Habashy, Berro, Takkoush, Abdelhady et al., Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury, Neuroscientist, doi:10.1177/1073858420961078
Shakoor, Feehan, Al Dhaheri, Ali, Platat et al., Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?, Maturitas
Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir. Res, doi:10.1016/j.antiviral.2013.06.002
Thomas, Patel, Bittel, Wolski, Wang et al., Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2021.0369
Vargas-Estrada, Gutierrez, Juarez-Rodriguez, Sumano, Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats, Arzneimittelforschung
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin alpha/betamediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J, doi:10.1042/BJ20120150
Wehbe, Hammoud, Soudani, Zaraket, El-Yazbi et al., Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling, Front. Pharmacol, doi:10.3389/fphar.2020.00836
Westblade, Brar, Pinheiro, Paidoussis, Rajan et al., SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19, Cancer Cell, doi:10.1016/j.ccell.2020.09.007
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer, Antivir. Res, doi:10.1016/j.antiviral.2020.104760
Younis, Zareef, Al Hassan, Bitar, Eid et al., Hydroxychloroquine in COVID-19 Patients: Pros and Cons, Front. Pharmacol, doi:10.3389/fphar.2020.597985
Zareef, Younis, Bitar, Eid, Arabi, COVID-19 in Pediatric Patients: A Focus on CHD Patients, Front. Cardiovasc. Med, doi:10.3389/fcvm.2020.612460
Zhang, Ni, Zhang, Xu, Gao et al., Ivermectin confers its cytotoxic effects by inducing AMPK/mTORmediated autophagy and DNA damage, Chemosphere, doi:10.1016/j.chemosphere.2020.127448
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop